Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials-Reference-Cited by-同舟云学术

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

Published:2013-07 Issue:7 Volume:13 Page:587-596
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Eron Joseph J,Cooper David A,Steigbigel Roy T,Clotet Bonaventura,Gatell Jose M,Kumar Princy N,Rockstroh Jurgen K,Schechter Mauro,Markowitz Martin,Yeni Patrick,Loutfy Mona R,Lazzarin Adriano,Lennox Jeffrey L,Strohmaier Kim M,Wan Hong,Barnard Richard JO,Nguyen Bach-Yen T,Teppler Hedy

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference16 articles.

1. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells;Hazuda;Science,2000

2. Merck. Prescribing information for ISENTRESS (raltegravir) tablets.

3. Raltegravir with optimized background therapy for resistant HIV-1 infection;Steigbigel;N Engl J Med,2008

4. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection;Cooper;N Engl J Med,2008

5. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials;Steigbigel;Clin Infect Dis,2010

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world prevalence of integrase inhibitor resistance and virological failure since adoption as guideline-preferred therapy;Drugs in Context;2024-05-16

2. Mind bomb 2 limits inflammatory dermatitis in Sharpin mutant mice independently of cell death;PNAS Nexus;2023-12-18

3. Conversion of raltegravir carrying a 1,3,4-oxadiazole ring to a hydrolysis product upon pH changes decreases its antiviral activity;PNAS Nexus;2023-12-18

4. Editorial to the Special Issue “Clinical Immunology in Italy, with Special Emphasis to Primary and Acquired Immunodeficiencies: A Commemorative Issue in Honor of Prof. Fernando Aiuti”;Biomedicines;2023-11-30

5. Long-term outcomes of highly experienced people with HIV undergoing salvage therapy with raltegravir;Medicine;2023-10-06